Nov. 22/99
SYNSORB Biotech Inc. Appoints Vice President, Clinical & Regulatory Affairs
CALGARY, ALBERTA--SYNSORB Biotech Inc. ("SYNSORB") (TSE: SYB,
Nasdaq: SYBB) today announced the appointment of John J. Frey,
Ph.D. to the position of Vice President, Clinical & Regulatory
Affairs, where his responsibilities will include all matters
pertaining to the development and conduct of the company's
clinical trials and regulatory filings, as well as its regulatory
strategy.
Dr. Frey is a business oriented scientist with over 27 years
experience in the pharmaceutical industry, including positions
with Pfizer Pharmaceuticals, New York, NY; Bristol-Myers
Pharmaceuticals, New York, NY; Johnson & Johnson: Ortho
Pharmaceutical Corporation, Raritan, NJ; and Ciba-Geigy
Pharmaceuticals, Summit, NJ. Most recently, Dr. Frey was
President and Principal Consultant at Health Products Development,
Lancaster, PA, providing consulting and contract services for
clinical development through attaining regulatory agency marketing
approvals for prescription health care products. Dr. Frey will
relocate to Calgary in early December.
Dr. Frey has expertise in a broad range of areas including the
management of clinical trials; regulatory submissions; regulatory
strategy and regulatory affairs; biostatistics; and
pharmaco-epidemiology. In addition, he has directly contributed
to the attainment of approval for numerous pharmaceutical products
and medical devices at the international level and with the US
Food and Drug Administration ("FDA").
"John Frey's experience in the management and successful
completion of clinical trials is extremely valuable to SYNSORB at
this stage in our clinical development programs," said David Cox,
Ph.D., President and Chief Executive Officer of SYNSORB. "His
proven track record of success in bringing products to market adds
an important element to SYNSORB's executive team. I am very
pleased to make this announcement and welcome Dr. Frey to
Calgary."
SYNSORB is a Canadian-based pharmaceutical company dedicated to
drug development and manufacturing. The Company has two
late-stage products, both of which are based on SYNSORB's
proprietary carbohydrate chemistry platform technology. SYNSORB
Pk is in Phase III clinical trials, and is designed to prevent the
progression to Hemolytic Uremic Syndrome (HUS) in children who
have contracted verotoxigenic E. coli (VTEC) infections, including
E. coli O157:H7. SYNSORB Cd will commence Phase III trials in the
first part of next year, and is designed to treat recurrent
antibiotic-associated diarrhea (CDAD), a common hospital acquired
infection. SYNSORB has built a cGMP-compliant manufacturing
facility that has the capacity to meet or exceed the expected
global demand for the Company's products. A pipeline of future
products is accessible through subsidiary companies and SYNSORB's
carbohybrid program.
This release contains certain forward-looking statements which
involve known and unknown risks, delays, uncertainties and other
factors not under the Company's control which may cause actual
results, performance or achievements of the Company to be
materially different from the results, performance or other
expectations implied by these forward-looking statements. These
factors include results of current or pending clinical trials,
actions by the FDA/HPB and those factors detailed in the Company's
registration statement on Form 20 F filed with the Securities and
Exchange Commission.
-30-
FOR FURTHER INFORMATION PLEASE CONTACT:
The Equicom Group
Jason Hogan
Investor Relations
(416) 815-0700 ex 222
(416) 815-0080 (FAX)
United States: 1-800-385-5451
jhogan@equicomgroup.com
or
SYNSORB Biotech Inc.
Cindy Gray
Investor Relations
(403) 270-1315
(403) 283-5907 (FAX)
cgray@synsorb.com
synsorb.com |
